Skip to main content
. 2017 Feb 25;8(4):691–703. doi: 10.7150/jca.17210

Table 2.

Meta-analysis Results for diarrhea.

Compared genotype Group No. of studies No. of participants OR
(95%CI)
P Test for heterogeneity
P I2
TA6/7 vs. TA6/6 All 28 3435 1.56
(1.25-1.96)
<0.001 0.175 19.9%
mCRC 16 2563 1.60
(1.11-2.31)
0.011 0.034 43.3%
SCLC 3 131 2.40
(0.74-7.74)
0.144 0.208 36.3%
mNSCLC 3 235 0.92
(0.34-2.54)
0.879 0.883 0.0%
Asian 18 2270 1.85
(1.37-2.50)
<0.001 0.334 10.1%
Caucasian 9 1118 1.28
(0.91-1.80)
0.117 0.136 35.3%
Retrospective 13 2123 1.70
(1.09-2.66)
0.020 0.032 46.8%
Prospective 12 1090 1.69
(1.13-2.52)
0.010 0.495 0.0%
TA7/7 vs. TA6/6 All 17 2610 3.97
(1.88-8.38)
<0.001 0.007 51.7%
mCRC 14 1172 3.53
(1.54-8.09)
0.003 0.004 57.5%
Asian 10 1805 8.98
(5.21-15.47)
<0.001 0.152 32.0%
Caucasian 7 805 1.09
(0.56-2.13)
0.807 0.259 22.3%
Retrospective 9 1737 4.84
(1.32-17.69)
0.017 <0.001 71.7%
Prospective 7 743 2.86
(1.30-6.30)
0.009 0.555 0.0%
TA6/7+7/7 vs. TA6/6 All 44 4868 2.18
(1.68-2.83)
<0.001 0.003 40.8%
SCLC 3 131 3.95
(1.42-11.01)
0.009 0.115 53.8%
mNSCLC 4 321 1.24
(0.58-2.65)
0.582 0.560 0.0%
Advanced OC 2 178 7.09
(2.91-17.26)
<0.001 1.00 0.0%
mCRC 25 3477 1.96
(1.42-2.70)
<0.001 0.005 47.3%
Asian 32 3607 2.74
(2.21-3.40)
<0.001 0.132 22.2%
Caucasian 11 1214 1.39
(0.84-2.32)
0.202 0.038 47.9%
Retrospective 16 2359 2.17
(1.36-3.49)
0.001 0.001 62.0%
Prospective 24 2198 2.12
(1.62-2.79)
<0.001 0.263 14.3%
TA7/7 vs. TA6/7+TA6/6 All 24 3175 3.64
(2.01-6.58)
<0.001 <0.001 57.6%
SCLC 2 64 19.90
(2.57-154.1)
0.004 0.832 0.0%
mCRC 17 2656 3.16
(1.61-6.19)
0.001 <0.001 64.1%
Asian 13 1917 8.64
(4.14-18.04)
<0.001 0.092 36.3%
Caucasian 10 1211 1.62
(1.03-2.53)
0.035 0.188 27.8%
Retrospective 11 2003 2.06
(1.23-3.44)
0.006 0.168 32.5%
Prospective 11 995 2.92
(1.64-5.21)
<0.001 0.219 26.2%

mCRC, metastatic colorectal cancer; mNSCLC, metastatic non-small-cell lung cancer.